Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study
- Dimopoulos, M.
- Wang, M.
- Maisnar, V.
- Minarik, J.
- Bensinger, W.
- Mateos, M.-V.
- Obreja, M.
- Blaedel, J.
- Moreau, P.
Revue:
Journal of Hematology and Oncology
ISSN: 1756-8722
Année de publication: 2018
Volumen: 11
Número: 1
Type: Article
